ReviewNature reviews. Neurology2022
Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours.
Review in Nature reviews. Neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 186 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
186 citing papers in PubMed, 3 syntheses or guidelines pooled it, 284 citations in OpenAlex.
- Pooled it
- Metabolic Imaging as Future Technology and Innovation in Brain-Tumour Surgery: A Systematic Review.Current oncology (Toronto, Ont.) · 2025Pooled it
- A systematic review of data sources for artificial intelligence applications in pediatric brain tumors in Europe: implications for bias and generalizability.Frontiers in oncology · 2023Pooled it
- Lower-grade gliomas surgery guided by GRPR-targeting PET/NIR dual-modality image probe: a prospective and single-arm clinical trial.Theranostics · 2024Trial
- Flash Assembloids: A Rapid Biofabrication of a Platform for Modeling Early Glioblastoma Invasion at the Glioblastoma-Brain Organoid Interfaces.Advanced healthcare materials · 2026Article
- Diagnostic Pitfalls of Oligodendroglioma-like Morphology: Integrated Reappraisal of 23 Non-Oligodendroglial Central Nervous System Tumors.Diagnostics (Basel, Switzerland) · 2026Article
- Platelet-to-Albumin Ratio and Clinical Outcomes in IDH-Wildtype Grade 4 Diffuse Glioma.Journal of clinical medicine · 2026Article
- Noninvasive Prediction ofDiagnostics (Basel, Switzerland) · 2026Article
- NR3C1 promotes group 4 medulloblastoma invasion via activating VCAN.Acta neuropathologica communications · 2026Article
- Tumor and Stromal Sphingolipid Imbalance Are Associated with T Cell Tissue Residency in Glioblastoma.Cancers · 2026Article
- Sphenoid Temporal Meningioma With Granular Cell Features and Extracranial Infratemporal Extension.Cureus · 2026Article
- A functionally guided fusion Vision Transformer for predicting IDH status in gliomas: a multicenter study with external validation and incomplete multimodal evaluation.Radiologie (Heidelberg, Germany) · 2026Article
- Label-Free Raman Spectroscopy Reveals Metabolic Signatures Associated with MGMT Promoter Methylation Status in Glioblastoma.Analytical chemistry · 2026Article
- Grade-Dependent Prognostic Value of Classical Clinicopathological Factors in Glioma: A Single-Center Retrospective Study.Journal of clinical medicine · 2026Article
- Hetairos is a histology-based artificial intelligence model for predicting central nervous system tumor methylation subtypes.Nature cancer · 2026Article
- Association of CDKN2A/B Homozygous Deletion and Extent of Resection With Survival of Patients With WHO CNS5 Grade 4 Astrocytoma.Annals of clinical and translational neurology · 2026Article
- X-optogenetic inhibition of VTA GABA neurons for wireless deep-brain stimulation and suppression of scratching behavior in freely moving mice.Materials today. Bio · 2026Article
- Integrated bulk and single-cell transcriptomic analyses identify transcriptome-defined groups and EGFR-associated microenvironmental programs in glioma.Discover oncology · 2026Article
- An EGFR co-amplified lncRNA HELDR promotes glioblastoma malignancy through KAT7-driven gene programs.Nature cell biology · 2026Article
- Fluorescence-aided stereotactic needle biopsies for brain tumors: experience on 516 cases.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
126 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
A new edition of the WHO classification of tumours of the CNS was published in 2021. Although the previous edition of this classification was published just 5 years earlier, in 2016, rapid advances in our understanding of the molecular underpinnings of CNS tumours, including the diversity of clinically relevant molecular types and subtypes, necessitated a new classification system. Compared with the 2016 scheme, the new classification incorporates even more molecular alterations into the diagnosis of many tumours and reorganizes gliomas into adult-type diffuse gliomas, paediatric-type diffuse low-grade and high-grade gliomas, circumscribed astrocytic gliomas, and ependymal tumours. A number of new entities are incorporated into the 2021 classification, especially tumours that preferentially or exclusively arise in the paediatric population. Such a substantial revision of the WHO scheme will have major implications for the diagnosis and treatment of patients with CNS tumours. In this Perspective, we summarize the main changes in the classification of diffuse and circumscribed gliomas, ependymomas, embryonal tumours and meningiomas, and discuss how each change will influence post-surgical treatment, clinical trial enrolment and cooperative studies. Although the 2021 WHO classification of CNS tumours is a major conceptual advance, its implementation on a routine clinical basis presents some challenges that will require innovative solutions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.